SCHEMBL3069585

SCHEMBL3069585

O=C(c1nc2c(C(F)(F)F)cc(-c3ccoc3)cn2c1Cl)N1CCC(N2C(=O)CNC2=O)CC1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.33
HSD11B1 P28845 1/20 0.32
TYRO3 Q06418 2/20 0.32
MERTK Q12866 2/20 0.32
RBP4 P02753 3/20 0.32
ALK Q9UM73 1/20 0.32
HDAC4 P56524 2/20 0.31
KDM5A P29375 1/20 0.31
MGLL Q99685 2/20 0.31
SCD5 Q86SK9 1/20 0.31
EPHX2 P34913 1/20 0.31
CHRM1 P11229 1/20 0.30
ERN1 O75460 1/20 0.30
MKNK1 Q9BUB5 1/20 0.30
MKNK2 Q9HBH9 1/20 0.30
GPR119 Q8TDV5 1/20 0.30
CCNC P24863 1/20 0.30
CDK8 P49336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3064728 0.90 TRPV1 (0.35) TRPV1HSD11B1TYRO3MERTKRBP4
SCHEMBL3067492 0.88 OXTR (0.33) TRPV1TYRO3MERTKRBP4
SCHEMBL3063651 0.87 F10 (0.34) TRPV1HSD11B1TYRO3MERTKRBP4
SCHEMBL3075488 0.86 TYRO3 (0.33) TRPV1TYRO3MERTKRBP4HDAC4
SCHEMBL3183940 0.86 TYRO3 (0.33) TRPV1TYRO3MERTKRBP4HDAC4
SCHEMBL3067818 0.86 TYRO3 (0.33) TRPV1TYRO3MERTKRBP4HDAC4
SCHEMBL3791014 0.85 L3MBTL3 (0.39) TRPV1ALK
SCHEMBL3058447 0.85 IRAK4 (0.36) TRPV1TYRO3MERTKRBP4KDM5A
SCHEMBL3063636 0.85 PROKR1 (0.34) RBP4ALKGPR119
SCHEMBL3785019 0.84 ENPP2 (0.37) TRPV1TYRO3MERTKRBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US claimed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO claimed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents BASKARAN SUBRAMANIAN 2010-10-28 US disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed
WO-2010091411-A1 PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272680-A1 Piperidinyl Cyclic Amido Antiviral Agents ZC3HAV1, MAVS, EIF2AK2 TRPV1 1739/4885HSD11B1 4679/4885TYRO3 3671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.